Increasing daily duration of rehabilitation for inpatients with sporadic inclusion body myositis may contribute to improvement in activities of daily living: A nationwide database cohort study
DOI:
https://doi.org/10.2340/jrm.v55.5289Keywords:
sporadic inclusion body myositis, rehabilitation, activities of daily living, intermediate variable analysis, duration of rehabilitationAbstract
Objective: To analyse the association between the daily duration of rehabilitation for inpatients with sporadic inclusion body myositis and improvement in activities of daily living, using a Japanese nationwide inpatient administrative claims database.
Methods: Data were extracted regarding inpatients with sporadic inclusion body myositis who had undergone rehabilitation between 1 April 2018 and 31 March 2021. The mean daily duration of rehabilitation was categorized into 2 groups: > 1.0 h (longer rehabilitation) and ≤ 1.0 h (shorter rehabilitation). The main outcome was improvement in activities of daily living from admission to discharge, measured using the Barthel Index. For the main analysis, a generalized linear model was used.
Results: In total, 424 patients with sporadic inclusion body myositis met the eligibility criteria for inclusion in the study. The main analysis found a significant difference in improvement in activities of daily living between the longer rehabilitation and shorter rehabilitation groups after adjusting for confounders (risk ratio (95% confidence interval), 1.37 (1.06–1.78)).
Conclusion: A longer daily duration of rehabilitation results in improved activities of daily living for inpatients with sporadic inclusion body myositis.
LAY ABSTRACT
Sporadic inclusion body myositis is a slowly progressive inflammatory myopathy. There is no known effective systemic therapy for sporadic inclusion body myositis; hence rehabilitation plays an important role in standard care for most patients. Although rehabilitation is currently provided to inpatients with the condition, there is almost no evidence for an association between the daily duration of rehabilitation and improvement in activities of daily living. The aim of this study was to evaluate the association between the daily duration of rehabilitation for inpatients with sporadic inclusion body myositis and improvement in activities of daily living, using a nationwide administrative database in Japan. The results show that a longer daily duration of rehabilitation results in improved activities of daily living for inpatients with sporadic inclusion body myositis.
Downloads
References
Dimachkie MM, Barohn RJ. Inclusion body myositis. Semin Neurol 2012; 32: 237–245. DOI: https://doi.org/10.1055/s-0032-1329197
Greenberg SA. Inclusion body myositis: clinical features and pathogenesis. Nat Rev Rheumatol 2019; 15: 257–272. DOI: https://doi.org/10.1038/s41584-019-0186-x
Dimachkie MM, Barohn RJ. Inclusion body myositis. Curr Neurol Neurosci Rep 2013; 13: 321. DOI: https://doi.org/10.1007/s11910-012-0321-4
Needham M, Mastaglia FL. Inclusion body myositis: current pathogenetic concepts and diagnostic and therapeutic approaches. Lancet Neurol 2007; 6: 620–631.
Paltiel AD, Ingvarsson E, Lee DK, Leff RL, Nowak RJ, Petschke KD, et al. Demographic and clinical features of inclusion body myositis in North America. Muscle Nerve 2015; 52: 527–533. DOI: https://doi.org/10.1002/mus.24562
Naddaf E, Barohn RJ, Dimachkie MM. Inclusion body myositis: update on pathogenesis and treatment. Neurotherapeutics 2018; 15: 995–1005. DOI: https://doi.org/10.1007/s13311-018-0658-8
Breithaupt M, Schmidt J. Update on treatment of inclusion body myositis. Curr Rheumatol Rep 2013; 15: 329. DOI: https://doi.org/10.1007/s11926-013-0329-z
Alexanderson H. Exercise in myositis. Curr Treatm Opt Rheumatol 2018; 4: 289–298. DOI: https://doi.org/10.1007/s40674-018-0113-3
Alexanderson H. Exercise in inflammatory myopathies, including inclusion body myositis. Curr Rheumatol Rep 2012; 14: 244–251. DOI: https://doi.org/10.1007/s11926-012-0248-4
Jeong JH, Yang DS, Koo JH, Hwang DJ, Cho JY, Kang EB. Effect of resistance exercise on muscle metabolism and autophagy in sIBM. Med Sci Sports Exerc 2017; 49: 1562–1571. DOI: https://doi.org/10.1249/MSS.0000000000001286
Mohannak N, Pattison G, Hird K, Needham M. Dysphagia in patients with sporadic inclusion body myositis: management challenges. Int J Gen Med 2019; 12: 465–474. DOI: https://doi.org/10.2147/IJGM.S198031
Jorgensen AN, Aagaard P, Frandsen U, Boyle E, Diederichsen LP. Blood-flow restricted resistance training in patients with sporadic inclusion body myositis: a randomized controlled trial. Scand J Rheumatol 2018; 47: 400–409. DOI: https://doi.org/10.1080/03009742.2017.1423109
Van Thillo A, Vulsteke JB, Van Assche D, Verschueren P, De Langhe E. Physical therapy in adult inflammatory myopathy patients: a systematic review. Clin Rheumatol 2019; 38: 2039–2051. DOI: https://doi.org/10.1007/s10067-019-04571-9
Alexanderson H, Bostrom C. Exercise therapy in patients with idiopathic inflammatory myopathies and systemic lupus erythematosus – a systematic literature review. Best Pract Res Clin Rheumatol 2020; 34: 101547. DOI: https://doi.org/10.1016/j.berh.2020.101547
Hayashida K, Murakami G, Matsuda S, Fushimi K. History and profile of diagnosis procedure combination (DPC): development of a real data collection system for acute inpatient care in Japan. J Epidemiol 2021; 31: 1–11. DOI: https://doi.org/10.2188/jea.JE20200288
Shinya M, Kenji F, Kiyohide F. Development of casemix based evaluation system in Japan. Asian Pacific J Dis Manag 2010; 4: 55–66. DOI: https://doi.org/10.7223/apjdm.4.55
Yasunaga H. Real world data in Japan: chapter II the diagnosis procedure combination database. Ann Clin Epidemiol 2019; 1: 76–79. DOI: https://doi.org/10.37737/ace.1.3_76
Wade DT, Collin C. The Barthel ADL Index: a standard measure of physical disability? Int Disabil Stud 1988; 10: 64–67. DOI: https://doi.org/10.3109/09638288809164105
Consultation WHOE. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 2004; 363: 157–163. DOI: https://doi.org/10.1016/S0140-6736(03)15268-3
Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005; 43: 1130–1139. DOI: https://doi.org/10.1097/01.mlr.0000182534.19832.83
Suzuki N, Soga T, Izumi R, Toyoshima M, Shibasaki M, Sato I, et al. Hybrid Assistive Limb(R) for sporadic inclusion body myositis: a case series. J Clin Neurosci 2020; 81: 92–94. DOI: https://doi.org/10.1016/j.jocn.2020.09.031
Chesnaye NC, Stel VS, Tripepi G, Dekker FW, Fu EL, Zoccali C, et al. An introduction to inverse probability of treatment weighting in observational research. Clin Kidney J. 2022;15(1): 14–20. DOI: https://doi.org/10.1093/ckj/sfab158
Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res 2011; 46: 399–424. DOI: https://doi.org/10.1080/00273171.2011.568786
Naimi AI, Whitcomb BW. Estimating risk ratios and risk differences using regression. Am J Epidemiol 2020; 189: 508–510. DOI: https://doi.org/10.1093/aje/kwaa044
Richiardi L, Bellocco R, Zugna D. Mediation analysis in epidemiology: methods, interpretation and bias. Int J Epidemiol 2013; 42: 1511–1519. DOI: https://doi.org/10.1093/ije/dyt127
Eba J, Nakamura K. Overview of the ethical guidelines for medical and biological research involving human subjects in Japan. Jpn J Clin Oncol 2022 31; 52(6): 539–544. DOI: https://doi.org/10.1093/jjco/hyac034
Tingley D, Yamamoto T, Hirose K, Keele L, Imai K. Mediation: R Package for causal mediation analysis. J Statist Software 2014; 59: 1–38. DOI: https://doi.org/10.18637/jss.v059.i05
Winstein CJ, Stein J, Arena R, Bates B, Cherney LR, Cramer SC, et al. Guidelines for adult stroke rehabilitation and recovery: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2016; 47: e98–e169. DOI: https://doi.org/10.1161/STR.0000000000000098
Cox FM, Titulaer MJ, Sont JK, Wintzen AR, Verschuuren JJ, Badrising UA. A 12-year follow-up in sporadic inclusion body myositis: an end stage with major disabilities. Brain 2011; 134: 3167–3175. DOI: https://doi.org/10.1093/brain/awr217
Carter GT. Rehabilitation management in neuromuscular disease. J Neurol Rehabil 1997; 11: 69–80.
Amato AA, Gronseth GS, Jackson CE, Wolfe GI, Katz JS, Bryan WW, et al. Inclusion body myositis: clinical and pathological boundaries. Ann Neurol 1996; 40: 581–586. DOI: https://doi.org/10.1002/ana.410400407
Johnson LG, Edwards DJ, Walters S, Thickbroom GW, Mastaglia FL. The effectiveness of an individualized, home-based functional exercise program for patients with sporadic inclusion body myositis. J Clin Neuromuscul Dis 2007; 8: 187–194. DOI: https://doi.org/10.1097/CND.0b013e3181237291
Johnson LG, Collier KE, Edwards DJ, Philippe DL, Eastwood PR, Walters SE, et al. Improvement in aerobic capacity after an exercise program in sporadic inclusion body myositis. J Clin Neuromuscul Dis 2009; 10: 178–184. DOI: https://doi.org/10.1097/CND.0b013e3181a23c86
Needham M, Mastaglia FL. Inclusion body myositis: current pathogenetic concepts and diagnostic and therapeutic approaches. Lancet Neurol 2007; 6: 620–631. DOI: https://doi.org/10.1016/S1474-4422(07)70171-0
Dalakas MC, Sonies B, Dambrosia J, Sekul E, Cupler E, Sivakumar K. Treatment of inclusion-body myositis with IVIg: a double-blind, placebo-controlled study. Neurology 1997; 48: 712–716. DOI: https://doi.org/10.1212/WNL.48.3.712
Benveniste O, Guiguet M, Freebody J, Dubourg O, Squier W, Maisonobe T, et al. Long-term observational study of sporadic inclusion body myositis. Brain 2011; 134: 3176–3184. DOI: https://doi.org/10.1093/brain/awr213
Dalakas MC, Koffman B, Fujii M, Spector S, Sivakumar K, Cupler E. A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM. Neurology 2001; 56: 323–327. DOI: https://doi.org/10.1212/WNL.56.3.323
Additional Files
Published
How to Cite
License
Copyright (c) 2023 Takuaki Tani, Shinobu Imai, Kiyohide Fushimi
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized JRM contents is available freely online. The Foundation for Rehabilitation Medicine owns the copyright for all material published until volume 40 (2008), as from volume 41 (2009) authors retain copyright to their work and as from volume 49 (2017) the journal has been published Open Access, under CC-BY-NC licences (unless otherwise specified). The CC-BY-NC licenses allow third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
From 2024, articles are published under the CC-BY licence. This license permits sharing, adapting, and using the material for any purpose, including commercial use, with the condition of providing full attribution to the original publication.
